SEC filing · 20-F

Haoxi Health Technology Ltd: Annual report (foreign issuer)

Haoxi Health Technology reported strong revenue growth for fiscal 2026 but swung to a net loss amid rising operating expenses and heavy supplier concentration.

Filed September 30, 2026 · period ended June 30, 2026

Mixed for the company

What the numbers say

Revenue rose 67% to $54.8M versus the prior year; operating margin narrowed from -6.1% to -17.6%; diluted EPS -$386.40 versus $3,385.53; operating cash flow -$2.6M (a year earlier -$3.4M); cash rose by $2.3M to $10.9M while debt fell by $317K; diluted share count up 2,537% (dilution).

Compared with the same period a year earlier, from the figures Haoxi Health Technology Ltd reported to the SEC.

What happened

Total revenue increased by $22.02 million, or 67.14%, to $54.83 million for the fiscal year ended June 30, 2026 from $32.80 million in fiscal 2025.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Haoxi Health Technology Ltd

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.